Abstracts

Yoshiie Matsumoto1, Yoshiaki Shiokawa1, Motoo Nagane2; 1Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, JAPAN

INTRODUCTION: Cerebellar glioblastoma (cGBM) is extremely rare, accounting for 0.7–0.9% of all gliomas. Few studies have reported on clinical course, histopathology, and prognosis. In this report, we discussed cases which were diagnosed as cGBM, and were treated in our institute.

Methods and Results: We retrospectively analyzed 9 cGBMs (age ranged 41 to 85 years, median 69), operated at our institute after 2010 January, and evaluated their <MGMT> promoter methylation, <IDH1> mutation, and Copy Number Variation status detected by methylation-specific PCR (MSP), DNA sequencing or immunohistochemistry, and Multiplex Ligation-dependent Probe Amplification (MLPA), respectively. RESULTS: All patients underwent resection; 3 gross total resections (GTRs, 33%), 2 subtotal resections, 4 partial resections, with relatively low achievement of GTR. The tumor location predominated in the cerebellar hemisphere (7 patients, 78%) over vermis (2). One patient had brain stem invasion. After surgery, 8 patients received temozolomide (TMZ) and radiotherapy (RT), while only one did RT alone. After recurrence, three patients were treated with bevacizumab monotherapy, and other three received either TMZ and RT, TMZ and ACNU, or TMZ monotherapy. The median progression-free survival (PFS) was 12.0 months, and the median overall survival (OS) was 17.1 months. Five patients (56%) were <MGMT> methylated, whereas all were <IDH1>-wild-type. <IDH1> deletion was negative in all patients. <EGFR> amplification and combination <PDGFR> amplification and <CDKN2A> deletion were found in one patient each. DISCUSSION: Despite the lower rate of GTR, there was a tendency of longer PFS compared to supratentorial GBM (gGBM). The clinical course after recurrence was unfavorable, and OS was similar to that of gGBM. cGBMs appeared to lack the typical genetic mutations occurred in gGBM, suggesting that cGBMs might be stimulated with different regulatory cellular signals.

BT-10

A RARE CASE OF RADIATION-INDUCED GLOBIATOMA

29 YEARS AFTER TREATMENTS OF GERMOMA

Ayaka Matsuo1, Ichiro Kawahara1, Takeshi Shiokawa1, Wataru Haraguchi1, Tomonori Ono1, Ryujiro Usuijima1, Keisuke Tsumumi1; 1Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center

BACKGROUND: Germinoma is one of the most radiosensitive tumors. Although radiotherapy (RT) can lead to long term survival, it has the possibility to cause adverse effects. One of the more serious side effects include radiation-induced tumors that can contribute to a life-long prognosis. Case presentation: A 40-year-old man was diagnosed with left basal ganglia germinoma at the age of 11 years old. Postoperatively, he received whole-brain radiotherapy 40Gy, focal radiotherapy 9.26Gy, and craniospinal irradiation 50Gy. Conclusion: The tumor developed in the previously irradiated field, with the attachment of the C3 dorsal root. Histopathological examination showed large supratentorial mass with cystic component and calcification. Gross total removal was achieved. She is well without recurrence on MRI one year after surgery. Case 2 is 42-year-old lady. She developed partial seizure. CT and MRI revealed a mass with ring-enhancement in the left temporal lobe. Gross total removal was achieved under awake craniotomy. She is well without recurrence on MRI six months after surgery. Pathologic examination of both patients showed pseudorosette formation of tumor cells around vasculature. Molecular analysis revealed rearrangement of MN-1 in case 1 but not in case 2. Case 2 showed BRAF V600E mutation and loss of CDKN2A/2B. Both patients received no adjuvant therapy.

CS-02

CLINICAL AND MOLECULAR ANALYSIS OF ASTROBLASTOMAS

Tomotsugu Ichikawa1, Satoshi Mino1, Naoya Kenmotsu1, Satoshi Kuramoto1, Yasuhiro Ono1, Masamitsu Kawazuch1, Kazuhiko Kurozumi, Isao Date, Akira Shimada, Satoko Nakamura, Hiroyuki Yani, Junko Hirato, Hideaki Yokose; 1Department of Neurosurgery, Kagawa Prefectural Central Hospital, Kagawa, Japan

Astroblastoma is extremely rare brain tumor which mostly arise in cerebral and cerebellum of children and young adult. Limited data exists on its clinical feature and molecular analysis. We recently experienced two female patients with astroblastoma in the cerebrum.

Case 1 is three-year-old girl. She developed left hemiparesis. CT and MRI revealed large supratentorial mass with cystic component and calcification. Gross total removal was achieved. She is well without recurrence on MRI one year after surgery. Case 2 is 42-year-old lady. She developed partial seizure. CT and MRI revealed a mass with ring-enhancement in the left temporal lobe. Gross total removal was achieved under awake craniotomy. She is well without recurrence on MRI six months after surgery. Pathologic examination of both patients showed pseudorosette formation of tumor cells around vasculature. Molecular analysis revealed rearrangement of MN-1 in case 1 but not in case 2. Case 2 showed BRAF V600E mutation and loss of CDKN2A/2B. Both patients received no adjuvant therapy.

Prognosis of astroblastoma varies and standard of treatment is not established. Gross total resection is associated with increased survival, but the role of adjuvant chemotherapy and radiation therapy are controversial. Advances in molecular analysis will lead to establish molecular classification and risk-adapted treatment strategy.

CS-03

LARGE CYSTIC INTRADURAL SCHWANNOMA IN CEREBRAL REGION: A CASE REPORT

Yuki Takeshima1, Tatsuma Takezaki, Tadashi Hamasaki, Seiji Tajiri1, Akatsuka Mukasa1, Takeshima Tatsuya; 1Department of Neurosurgery, Kagoshima City General Hospital and Medical Center, Kagoshima, Japan

Schwannomas are the most common intradural extramedullary spinal tumors. However, they are usually solid tumors, and totally cystic schwannomas are rare. Herein, we report a case of a 46-year-old male presenting with numbness of right limbs, right hemiplegia, and posterior neck pain for one year. MRI revealed a well-defined cystic long-segment, from C1 to C6, intradural extramedullary mass. The lesion showed hypointense on TIWI, hyperintense on T2WI, hyperintense on DWI, and it was marginally enhanced on the contrast image with Gd-DTPA. C1 laminectomy and hemi-laminectomy from C1 to C6 were performed and the pathological diagnosis was giant cell tumor. Patient received no adjuvant treatment. The patient has been on good course for 5 years without recurrence and is still following-up.

CS-04

INTEGRATED CLINICAL, HISTOPATHOLOGICAL, AND MOLECULAR DATA ANALYSIS OF 190 CENTRAL NERVOUS SYSTEM GERM CELL TUMORS FROM THE IGCt CONSORTIUM

Hirokazu Takechi1, Kohei Kurosawa1, Akatsuka Mukasa1, Nobuhito Soito, Soichiro Shibui, Yoichi Nakazato, Hideaki Yokose1; 1Department of Neurosurgery, Kagawa Prefectural Central Hospital, Kagawa, Japan

Giant cell tumor of bone is a rare and osteolytic neoplasm that usually affects the epiphyses in long bones of the extremities. They seldom occur in the skull, preferentially affecting the sphenoid and temporal bones. Most pathologically benign, and total removal by surgery was regarded as the first treatment, however, it was very difficult in skull lesion. In 2014 the molecular targeted drug anti-RANKL inhibitor was approved in Japan. We report a case in which an anti-RANKL inhibitor was administered to a skull base bone giant cell tumor that was difficult to remove completely. A 56-year-old man with a sudden right neck pain followed by dysphoria and dysphagia was referred to our hospital. Computed tomography showed 4.4 x 2.0 cm osteolytic lesion involving the right occipital bone and occipital condyle. Magnetic resonance imaging demonstrated an extensive soft-tissue mass occupying. Surgical biopsy was performed and the pathological diagnosis was giant cell tumor. Patient received the anti-RANKL inhibitor (Denosumab)1. After 6 weeks, improvement was observed, and neurological symptoms were improved after 12 weeks. Patient has been on good course for 5 years without recurrence and is still following-up.